类风湿关节炎治疗药物的研究进展被引量：18

Advances in research on drugs for the treatment of rheumatoid arthritis

导出

摘要近年来,类风湿关节炎治疗药物的研发有较大进展。肿瘤坏死因子-α(TNF-α)抑制剂、白介素(IL)抑制剂、蛋白酶抑制剂和改善病情抗风湿药都有新品种出现,并且在临床广泛应用。本文对上述药物的临床疗效和安全性做一综述。 Research on drugs for the treatment of rheumatoid arthritis has made significant progress in recent years. New drugs, such as tumor necrosis factor α（TNF-α） inhibitors, interleukin inhibitors, protease inhibitors and disease-improving antirheumatic drugs are developed and have been widely used clinically. Clinical efficacy and safety of these drugs are reviewed in this paper.

作者兰芬阳凌燕管剑龙

机构地区第二军医大学长海医院药学部复旦大学附属华东医院风湿免疫科

出处《药学服务与研究》 CAS CSCD 2013年第1期38-42,共5页 Pharmaceutical Care and Research

关键词类风湿关节炎抑制剂肿瘤坏死因子抑制剂白介素改善病情抗风湿药综述 rheumatoid arthritis inhibitor, tumor necrosis factor inhibitor interleukin disease-improving antirheumatic drugs review

分类号 R593.22 [医药卫生—内科学]

引文网络
相关文献

参考文献25

1Soubrier M, Puechal X, Sibilia J, et al. Evaluation of two strategies(initial methotrexate mortotherapy us its combina- tion with adalimumab) in management of early active rheuma- toid arthritis:data from the GUEPARD trial[J]. Rheumatolo- gy,2009,48(9) :1429 -1434.
2Breedveld F C, Weisman M H, Kavanaugh A F, et al. The PREMIER study- a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumah alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment[J]. Arthritis Rheum, 2006,54 ( 1 ) : 26-37.
3Kaneko A, Hirano Y, Fujibayashi T,et al. Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice[J]. Mod Rheumatol, 2012, Epub ahead of print.
4Chara L, Sanchez-Atrio A, Perez A,et al. Monocyte popula- tions as markers of response to adalimumab plus MTX in rheumatoid arthritis [J]. Arthritis Res Ther, 2012,14 ( 4 ) R175.
5Karateev D E, Nasonov E L, Luchikhina E L, et al. The effi- ciency and safety of adalimumah treatment in patients with active rheumatoid arthritis unresponsive to standard therapy: Russian national study results[J]. Ter Arkh,2012,84(8) :22- 28.
6Pomirleanu C, Ancuta C, Maeovei L,et al. Prospective study of the efficiency and safety of adalimumab in treatment of ac- tive established rheumatoid arthritis[J]. Rev Med Chir Soc Med Nat Iasi,2012,116(2):395-400.
7Schmitz S, Adams R, Walsh C D, et al, A mixed treatment comparison of the efficacy of anti TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments:a Bayesian approach[J]. Ann Rheum Dis,2012,71(2) :225-230.
8Hetland M L,Christensen I J,Tarp U,et al. Direct compari- son of treatment responses, remission rates, and drug adher- ence in patients with rheumatoid arthritis treated with adali- mumab, etanercept, or infliximab : results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry[J]. Arthritis Rheum, 2010,62 (1) : 22-32.
9Dixon W G, Hyrich K L,Watson K D,et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)[J]. Ann Rheum Dis,2010,69(3) ,522-528.
10Askling J ,van Vollenhoven R F,Granath F,et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: dose the risk change with the time since start of treatment? [J]. Arthritis Rheum, 2009,60 (11) :3180-3189.